search icon
      blog search icon

      Here is why Aprea Therapeutics Inc. (APRE) stock surged on Friday? - Stocks Telegraph

      By Asim Kamal

      Published on

      September 20, 2021

      5:29 AM UTC

      Here is why Aprea Therapeutics Inc. (APRE) stock surged on Friday? - Stocks Telegraph

      Aprea Therapeutics Inc. (APRE) shares soared 16.40% in after-hours on Friday, September 17, 2021, and closed the trading at $5.89. Even in the regular trading session of Friday, APRE’s stock gained 4.55% to close Friday’s session at $5.6. APRE shares have fallen 82.71% over the last 12 months, and they have moved up 10.24% in the past week. Over the past three months, the stock has gained 4.98%, while over the past six months, it has declined 11.23%.

      Let’s have a look at its recent news and developments.

      APRE recent presentation at ESMO

      Aprea Therapeutics, Inc. (APRE), presented data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumours at the European Society of Medical Oncology (ESMO) Congress 2021 which is scheduled for September 16 – 21, 2021.

      APRE Q2 2021 financial results announcement

      On August 12, 2021, Aprea Therapeutics, Inc. (APRE) released financial results for the three and six months ended June 30, 2021.

      Q2 2021 financial highlights

      • Research and development expenses were $6.7 million in Q2 2021 compared to $10.7 million for the comparable period in 2020.
      • General and administrative expenses were $3.4 million for Q2 2021 compared to 3.8 million in Q2 2020.
      • It suffered a net loss of $10.3 million, or $0.48 per share for Q2 2021 compared to a net loss of $16.4 million, or $0.78 per share in the same quarter in 2020.
      • The company had 69.8 million cash and cash equivalents on June 30, 2021, compared to $89.0 million of cash and cash equivalents as of December 31, 2020.

      Update about APRE Lymphoid Malignancy Program

      On August 12, 2021, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Aprea Therapeutics, Inc. (APRE) clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. No additional patients can be enrolled until the clinical hold is resolved, though patients on study deriving clinical benefit can continue to receive study treatment.

      Update about APRE Myeloid Malignancy Programs

      On August 05, 2021, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on Aprea Therapeutics, Inc (APRE) clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company’s ongoing clinical trials in lymphoid malignancies and solid tumours or the APR-548 clinical trial.

      Phase 2 trial results of APRE eprenetapopt with azacitidine

      On July 21, 2021, Aprea Therapeutics, Inc. (APRE) announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML.

      The relapse-free survival (RFS) at 1-year post-transplant was 58% and the median RFS was 12.1 months for the 33 patients enrolled in the trial. The overall survival (OS) at 1-year post-transplant was 79%, with a median OS of 19.3 months.

      Conclusion

      The recent data presentation at ESMO could be the reason behind its gains on Friday and we hope that it will continue its performance after the weekend on Monday.

      More From Stocks telegraph